As the first orexin-2 receptor agonist nears FDA approval, preclinical compound BP1.15205 shows promise for its higher potency.| Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review